CompletedNCT00753012
Heart effects of lisdexamfetamine in adults with ADHD
About this title
Read the official source — NCT00753012Medication studyAges 18–60United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 60 years.
- Listed locations
- CambridgeSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateApril 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 24
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT00753012
- Official title
Show the full official title
An In Depth Cardiovascular Study of Lisdexamfetamine (LDX; Vyvanse) in Healthy and Treated Hypertensive Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cambridge
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Lisdexamfetamine.
Who was this study for?
Listed age limits: 18 years to 60 years.
